To truly improve patients’ lives through personalized medicine, the seeds of innovation must be sown, and its capacity must be grown. Europe undoubtedly excels as an R&D hub, yet we fall behind when transforming ideas into tangible products and services. So how can we create an environment where personalized medicine can flourish and deliver real solutions for patients? That question was the focus of a recent meeting at the European Parliament where the PRECISEU consortium brought together key stakeholders to discuss the future of the field.
Belgium’s flagship “biology meets technology” conference returns to Brussels this fall with a clear message: collaboration is key to keeping Europe at the front of health innovation. On 4 November 2025, Science for Health will explore how Belgium’s regional strengths and synergies can be combined to accelerate ATMP and new modalities—such as radioligand therapies and digital health solutions—to reinforce the country's global position in biotech and healthtech.
Buses full of innovators, lab doors wide open and conversations to spark collaboration—that was the vibe for BioWin on Tour on 24 September 2025, co-organized with AWEX. It was a whirlwind visit, with fifty international delegates from nine countries visiting two of Wallonia’s flagship science hubs—LégiaPark and BioPark Charleroi—discovering the region’s twin strengths of ATMPs and nuclear medicine.
Biovia is Europe’s first industry-led One Health innovation cluster—uniting medical biotech, medtech, digital health, agtech and industrial biotech to advance human and planetary health. Katrien Lorré explains how this unified approach benefits companies by unlocking opportunities and fostering a better environment for health innovation.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Every start-up team ponders the all-important question: how to convince investors to fund their idea? Currently, the fundraising landscape is particularly challenging for most early-stage biotech ventures. A fortunate few are raising exorbitant rounds, allowing them to advance their products through preclinical development, but many others are struggling to find the funding they require. In this article, we share our investor perspective on what can help companies to stand out from the crowd, given recent advancements in drug development.
A world where we can 3D bioprint organs on demand is creeping ever closer to clinical reality, thanks to Belgian efforts to standardize the biomaterials necessary. Achieving this will have profound consequences for organ transplants, disease modeling, tissue engineering, personalized medicine, and drug discovery. But bioprinting success depends on multidisciplinary collaborations between material scientists, hardware manufacturers, clinicians, and other partners. Recently, these collaborations have reached the stratosphere, with a project to study cardiovascular aging with a heart-on-a-chip… in space!
Cervical cancer is largely curable if detected early enough and yet it remains a leading cause of death in women globally. Why? Although researchers recently made the biggest improvement in cervical cancer treatment in more than 20 years, cutting the risk of death by over 40%, effective and inclusive screening remains crucial for early detection and treatment. However, recent research from Belgium suggests that certain populations of vulnerable women or those with a migration background are falling through the cervical cancer screening cracks.
To truly improve patients’ lives through personalized medicine, the seeds of innovation must be sown, and its capacity must be grown. Europe undoubtedly excels as an R&D hub, yet we fall behind when transforming ideas into tangible products and services. So how can we create an environment where personalized medicine can flourish and deliver real solutions for patients? That question was the focus of a recent meeting at the European Parliament where the PRECISEU consortium brought together key stakeholders to discuss the future of the field.
Belgium’s flagship “biology meets technology” conference returns to Brussels this fall with a clear message: collaboration is key to keeping Europe at the front of health innovation. On 4 November 2025, Science for Health will explore how Belgium’s regional strengths and synergies can be combined to accelerate ATMP and new modalities—such as radioligand therapies and digital health solutions—to reinforce the country's global position in biotech and healthtech.
Buses full of innovators, lab doors wide open and conversations to spark collaboration—that was the vibe for BioWin on Tour on 24 September 2025, co-organized with AWEX. It was a whirlwind visit, with fifty international delegates from nine countries visiting two of Wallonia’s flagship science hubs—LégiaPark and BioPark Charleroi—discovering the region’s twin strengths of ATMPs and nuclear medicine.
Biovia is Europe’s first industry-led One Health innovation cluster—uniting medical biotech, medtech, digital health, agtech and industrial biotech to advance human and planetary health. Katrien Lorré explains how this unified approach benefits companies by unlocking opportunities and fostering a better environment for health innovation.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Every start-up team ponders the all-important question: how to convince investors to fund their idea? Currently, the fundraising landscape is particularly challenging for most early-stage biotech ventures. A fortunate few are raising exorbitant rounds, allowing them to advance their products through preclinical development, but many others are struggling to find the funding they require. In this article, we share our investor perspective on what can help companies to stand out from the crowd, given recent advancements in drug development.
A world where we can 3D bioprint organs on demand is creeping ever closer to clinical reality, thanks to Belgian efforts to standardize the biomaterials necessary. Achieving this will have profound consequences for organ transplants, disease modeling, tissue engineering, personalized medicine, and drug discovery. But bioprinting success depends on multidisciplinary collaborations between material scientists, hardware manufacturers, clinicians, and other partners. Recently, these collaborations have reached the stratosphere, with a project to study cardiovascular aging with a heart-on-a-chip… in space!
Cervical cancer is largely curable if detected early enough and yet it remains a leading cause of death in women globally. Why? Although researchers recently made the biggest improvement in cervical cancer treatment in more than 20 years, cutting the risk of death by over 40%, effective and inclusive screening remains crucial for early detection and treatment. However, recent research from Belgium suggests that certain populations of vulnerable women or those with a migration background are falling through the cervical cancer screening cracks.